Crossmark

A Response to: Letter to the Editor Regarding “Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)”

Crossref DOI link: https://doi.org/10.1007/s40119-024-00383-4

Published Online: 2024-10-23

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Attal, Sepideh
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2024-10-23

Version of Record valid from 2024-10-23
More Information

Article History

Received: 30 July 2024

Accepted: 4 September 2024

First Online: 23 October 2024

Declarations

:

: Sepideh Attal is an employee of Pfizer and holds stock/stock options.

: This letter is based on a previously conducted study and does not contain any new studies with human participants or animals performed by the author.

Document is current

Any future updates will be listed below